Loading...
 

January - March 2017: 
Volume 30, Issue 1

Click on the image to download the Issue in PDF format.

ARCHIVE

Pneumon 2017, 30(1):32-40
Prevention of Invasive Pneumococcal Disease (IPD)
Authors Information

1: 2nd Pulmonary Department, “ATTIKON” University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece
2: Pulmonary Medicine Department, General Hospital of Pireaus, Pireaus , Greece
3: Associate Professor, Department of Critical Care, “Attikon” University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Abstract
Streptococcus pneumoniae consists of a major cause of community-acquired pneumonia in the elderly, resulting in considerable morbidity and mortality worldwide. Although pneumococcal community-acquired pneumonia presents usually as non-bacteremic disease, invasive pneumococcal disease (IPD) concerns infection of normally sterile sites, such as blood or cerebral fluid. The risk for Invasive Pneumococcal Disease increases in particular groups of patients, including hematologic malignancies, infection with human immu-nodeficiency virus (HIV), asplenia - functional or anatomic, chronic diseases and extreme ages (65 years old). The prevention against IPD is achieved by vaccines against Streptococcus pneumoniae. Today, there are two available types of vaccines, the polysaccharide pneumonococcus vaccine (PPSV23 and the pneumonococcus con-jugated vaccine (PCV13).